medicalmarketnews.com
Biogen Aims to Purchase Pfizer's Nascent Treatment for Alzheimer’s and Parkinson's - Medical Market News
Biogen stated Monday it has agreed to purchase an early-stage experimental treatment from Pfizer that it intends to test in people who have Alzheimer’s and Parkinson’s disease. Under the agreement, Pfizer will get $75 million upfront and will be eligible for $635 million in potential milestone payments. Biogen stated it aims to develop the early-stage …